Evidence map›Paper›PMID 41168449›Full record

ArticleAnnals of hematology2025

Venetoclax-based chemotherapy failure in adult T-cell acute lymphoblastic leukemia with NUP98::ADD3 fusion: a case report.

Ting Shi, Zhanrui Cheng, Zhiyao Zhang, Xingran Jiang, Yantian Zhao, Yin Wu, Hong-Hu Zhu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. RareAmerican journal of cancer research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ting Shi *Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
Zhanrui Cheng *Chinese Institutes for Medical Research, Beijing, 100005, China.
Zhiyao ZhangDepartment of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
Xingran JiangDepartment of Pathology, Beijing ChaoYang Hospital, Capital Medical University, No. 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
Yantian ZhaoDepartment of Clinical Laboratory, Beijing ChaoYang Hospital, Capital Medical University, No. 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China.
Yin WuDepartment of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. wudxuan@126.com.
Hong-Hu ZhuDepartment of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. zhuhhdoc@163.com.

Funding

Beijing Chao-Yang Hospital Golden Seeds Foundation CYJZ202317Beijing Hospitals Authority "Dengfeng" talent training plan DFL20240301Beijing Municipal Administration of Hospitals Incubating Program PX2025005the National Natural Science Foundation of China 82400197
6 · The paper itself

Abstract

NUP98 fusions are molecularly rare in T-cell acute lymphoblastic leukemia (T-ALL), with limited data available regarding treatment response and clinical outcomes. Here, we report a case of T-ALL harboring a NUP98::ADD3 fusion (involving NUP98 exon 13 and ADD3 exon 13), representing only the second documented instance of this genetic rearrangement in T-ALL. Notably, the patient demonstrated refractoriness to venetoclax-based chemotherapy. To our knowledge, this is the first report of a T-ALL case with the NUP98::ADD3 fusion exhibiting resistance to venetoclax-containing regimens.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicNuclear Pore Complex ProteinsOncogene Proteins, FusionPrecursor T-Cell Lymphoblastic Leukemia-LymphomaSulfonamidesAdultDrug Resistance, NeoplasmHumansMaleTreatment FailureBridged Bicyclo Compounds, HeterocyclicNuclear Pore Complex ProteinsNup98 protein, humanOncogene Proteins, FusionSulfonamidesvenetoclax

Identifiers

PMID41168449
PMCPMC12672683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.